Management of acute hyperkalaemia: evidence, practice and pitfalls
- 1Royal Brisbane and Women’s Hospital
- 2The University of Queensland, Brisbane
Abstract
SUMMARY: Acute hyperkalaemia is a medical emergency requiring rapid clinical evaluation. Point-of-care blood gas analysis may overestimate serum potassium concentration and should be confirmed with a laboratory sample unless urgent treatment is required.
When ECG (electrocardiogram) changes are present, immediate cardiac protection is a priority. Current guidelines recommend administering intravenous 10% calcium gluconate to restore cardiac conduction velocity.
Intravenous insulin rapidly shifts potassium into cells. It is given with intravenous dextrose to reduce the risk of hypoglycaemia. A reduced insulin dose can be considered in patients with significant kidney dysfunction.
Salbutamol shifts potassium into cells and has a synergistic effect with insulin. Nebulised salbutamol administration offers similar efficacy to intravenous delivery with fewer adverse effects.
The routine use of intravenous sodium bicarbonate or oral potassium binders is not recommended for immediate lowering of serum potassium in acute hyperkalaemia. Sodium bicarbonate should be reserved as an adjunctive treatment for patients with concurrent metabolic acidosis.
Post-acute care focuses on addressing reversible triggers and, once hyperkalaemia resolves, restarting important drugs that can increase potassium concentrations, if their benefit outweighs the risk (e.g. renin–angiotensin–aldosterone system inhibitors).
Related
- Organ Preservation in Rectal Adenocarcinoma—A Growing Practice With Promise and Pitfalls
- A general practice-centred model for early diagnosis and management of Alzheimer's disease in Denmark: rationale, evidence and a pragmatic diagnostic approach.
- Management of dysglycemia in critically ill adults: current evidence, clinical practice and future directions
- Update of Korean Medicine Clinical Practice Guidelines for Obesity Management: An Evidence‐Based GRADE Approach
- Improving immunosuppressant medication compliance management in adult kidney transplant patients: an evidence-based practice project.
BibTeX
@article{ford2026management,
title = {{Management of acute hyperkalaemia: evidence, practice and pitfalls}},
author = {Samuel Ford and Anna Zipf and Julian Williams},
journal = {Australian Prescriber},
year = {2026},
month = oct,
doi = {10.18773/austprescr.2026.040},
url = {https://doi.org/10.18773/austprescr.2026.040},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Management of acute hyperkalaemia: evidence, practice and pitfalls
AU - Samuel Ford
AU - Anna Zipf
AU - Julian Williams
PY - 2026
DA - 2026/10/01
JO - Australian Prescriber
DO - 10.18773/austprescr.2026.040
UR - https://doi.org/10.18773/austprescr.2026.040
AB - SUMMARY: Acute hyperkalaemia is a medical emergency requiring rapid clinical evaluation. Point-of-care blood gas analysis may overestimate serum potassium concentration and should be confirmed with a laboratory sample unless urgent treatment is required. When ECG (electrocardiogram) changes are present, immediate cardiac protection is a priority. Current guidelines recommend administering intravenous 10% calcium gluconate to restore cardiac conduction velocity. Intravenous insulin rapidly shifts potassium into cells. It is given with intravenous dextrose to reduce the risk of hypoglycaemia. A reduced insulin dose can be considered in patients with significant kidney dysfunction. Salbutamol shifts potassium into cells and has a synergistic effect with insulin. Nebulised salbutamol administration offers similar efficacy to intravenous delivery with fewer adverse effects. The routine use of intravenous sodium bicarbonate or oral potassium binders is not recommended for immediate lowering of serum potassium in acute hyperkalaemia. Sodium bicarbonate should be reserved as an adjunctive treatment for patients with concurrent metabolic acidosis. Post-acute care focuses on addressing reversible triggers and, once hyperkalaemia resolves, restarting important drugs that can increase potassium concentrations, if their benefit outweighs the risk (e.g. renin–angiotensin–aldosterone system inhibitors).
SN - 0312-8008
SN - 1839-3942
ER -